Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1233-1239

  Lee, R S ^a   Schlumberger, M ^b   Caillou, B ^b   Pages, F ^a   Fridman, W H ^a   Tartour, E ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

immunophenotype; thyroid tumour; tumour infiltrating lymphocytes

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CHROMOSOME TRANSLOCATION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOPHENOTYPING; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; THYROID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; VIRUS TRANSFORMATION;

EID: 0030176130     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00017-2     Document Type: Article

References (36)

1. 1. Thompson DE, Mabuchi K, Ron E, et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumours, 1958-1987. Radiat Res 1994, 137, S17-S67.
2. 2. Williams D. Chernobyl, eight years on. Nature 1994, 371, 556.
3. 3. Wynford-Thomas D. Molecular basis of epithelium tumorigenesis: the thyroid model. Crit Rev Oncol 1993, 4, 1-23.
4. 4. Correa P, Chen VW. Endocrine gland cancer. Cancer 1995, 75, 338-352.
5. 5. Aguayo J, Sakatsume Y, Jamieson C, Row VV, Volpe R. Non toxic nodular goiter and papillary thyroid carcinoma are not associated with peripheral blood lymphocyte sensitization to thyroid cells. J Clin Endocrinol Metab 1989, 68, 145-149.
6. 6. Pacini F, Elisei R, Di Coscio GC, et al. Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest 1988, 11, 107-113.
7. 7. Amino N, Pysher T, Cohen EP, Degroot LJ. Immunologic aspects of human thyroid cancer. Humoral and cell-mediated immunity, and a trial of immunotherapy. Cancer 1975, 36, 963-973.
8. 8. Pardoll DM. A new look for the 1990s. Nature 1994, 369, 357-358.
9. 9. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 10, 1338-1343.
10. 10. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987, 123, 1053-1055.
11. 11. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983, 9, 689-696.
12. 12. Rosenberg SA, Yanelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994, 15, 1159-1166.
13. 13. Thiounn N, Mathiot C, Tartour E, et al. Phenotypic and functional analysis of tumour infiltrating lymphocytes (TIL) from patients with renal cell carcinoma. Eur Urol 1994, 25, 151-157.
14. 14. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993, 53, 5610-5612.
15. 1ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993, 53, 5613-5616.
16. 16. Tartour E, Latour S, Mathiot C, et al. Variable expression of CD3-ζ chain in tumor infiltrating lymphocytes (TIL) derived from renal cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995, 63, 205-212.
17. 17. Mathiot C, Robin E, Gey A, et al. Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with melanoma and other metastatic cancers. Eur J Cancer 1992, 28, 345-350.
18. 18. Bagnasco M, Venuti D, Paolieri F, Torre G, Ferrini S, Canonica GW. Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity. J Clin Endocrinol Metab 1989, 69, 832-836.
19. 19. Maleckar JR, Friddell CS, Sferruzza A, et al. Activation and expansion of tumor-derived activated cells for therapeutic use. J Natl Cancer Inst 1989, 81, 1655-1660.
20. 20. Betterle C, Presotto F, Caretto A, et al. Expression of class I and II human leukocyte antigens by thyrocytes and lymphocytic infiltration on human thyroid tumors. Cancer 1991, 67, 977-983.
21. 21. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol 1989, 7, 445-480.
22. 22. Herin M, Lemoine C, Weynants P. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 1987, 39, 390-396.
23. 23. Wallace LE, Rickinson AB, Rowe M, Moss DJ, Allen DJ, Epstein MA. Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr-Virus transformed cell line. I Virus-specific and non-specific components of the cytotoxic response. Cell Immunol 1982, 67, 129-140.
24. 24. Ghosch AK, Moore M. Tumour-infiltrating lymphocytes in cervical carcinoma. Eur J Cancer 1992, 28A, 1910-1916.
25. 25. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 1986, 164, 351-356.
26. 26. Barnaba V, Franco A, Paroli M, et al. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J Immunol 1994, 152, 3074-3087.
27. 27. Lanier LL, Le AM, Ding A, et al. Expression of Leu-19 (NKH-1) antigen on IL2-dependent cytotoxic and non-cytotoxic T cell lines. J Immunol 1987, 138, 2019-2023.
28. 28. Heo DS, Whiteside TL, Kanbour A, Herberman RB. Lymphocytes infiltrating human ovarian tumors. I Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating ovarian tumors. J Immunol 1988, 140, 4042-4049.
29. - cells, in autoimmune thyroid disease. Clin Exp Immunol 1993, 93, 430-436.
30. + T-cell clones. Nature 1988, 335, 642-644.
31. 31. Tang H, Matthes T, Carballido-Perrig N, Zubler RH, Kindler V. Differential induction of T cell cytokine mRNA in Epstein-Barr virus-transformed B cell clones: constitutive and inducible expression of interleukin-4 mRNA. Eur J Immunol 1993, 23, 899-903.
32. 32. Boyd RL, Hugo P. Towards an integrated view of thymopoieisis. Immunol Today 1991, 12, 71-79.
33. +) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2 responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. Aclonal analysis. Eur J Immunol 1987, 17, 1815-1819.
34. 34. Berrih S, Gaud C, Bach MA, Le Brigand H, Binet JP, Bach JF. Evaluation of T cell subsets in myasthenia gravis using anti-T cell monoclonal antibodies. Clin Exp Immunol 1981, 45, 1-8.
35. 35. Ottenhoff THM, Elferink DG, Klatser PR, de Vries RRP. Cloned suppressor T cells from a lepromatous leprosy patient suppress Mycobacterium leprae reactive T cells. Nature 1986, 322, 462-464.
36. 36. Gedde-Dahl III T, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-Leu 61). Int Immunol 1992, 4, 1331-1337.